Effect of 3-aminobenzamide on perforation an experimental colitis model.

doi:10.5152/tjg.2014.4288

Paper

Effect of 3-aminobenzamide on perforation an experimental colitis model.

Published Apr 22, 2015 · E. Menekşe, S. Aydin, A. Sepici Dinçel

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology

Q3 SJR score

3

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

BACKGROUND/AIMS The anti-inflammatory activity of 3-aminobenzamide (3-AB) has been shown via histopathology and immunohistochemistry in various colitis models. We aimed to study the effects of 3-AB on tissue mechanical endurance and, associatively, preventing perforation in colitis. MATERIALS AND METHODS Thirty male Wistar albino rats were randomly divided into three groups. Rectal saline was administered to Group 1 (sham+saline). Rectal trinitrobenzensulphonic acid was applied to induce colitis in Group 2 (colitis+saline) and Group 3 (colitis+3-AB). Groups 1 and 2 were treated intraperitoneally with saline (1 ml every 12 hours) and Group 3 was treated with 3-AB (10 mg/kg every 12 hours). After seven days, rats were sacrificed and colon lipid peroxidation levels, the serum tumor necrosis factor alpha (TNF-α) level, bowel bursting pressures, and bowel wall tensions were measured. RESULTS Bowel bursting pressure in Group 2 was significantly lower than in Groups 1 and 3 (p<0.001 for both groups). Bowel wall tension in Group 2 was significantly lower than in Groups 1 and 3 (p<0.001 for both groups). There were no significant differences between groups for serum TNF-α levels. For lipid peroxidation, malondialdehyde (MDA) levels were increased in Groups 2 and 3 compared to Group 1. CONCLUSION 3-AB may aid prevention of perforations that develop in inflammatory bowel disease, requiring surgical treatment.

RCT

Animal Study

Study Snapshot

3-aminobenzamide may help prevent perforations in inflammatory bowel disease, potentially reducing the need for surgical treatment.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Effect of 3-aminobenzamide on perforation an experimental colitis model.

Sign up to use Study Snapshot

References

Current treatment of ulcerative colitis.

Ulcerative colitis treatment varies based on severity, localization, and course, with topical therapy for proctitis, oral and local 5-ASA compounds, corticosteroids, and hospitalization for refractory cases.

Poly(ADP-Ribose) Polymerase-1: A Novel Therapeutic Target in Necrotizing Enterocolitis

Nicotinamide treatment protects newborn rats from intestinal injury in a newborn rat necrotizing enterocolitis model, suggesting PARP-1 overactivation may drive mucosal cell death in this disease.

Treatment of inflammatory bowel disease (IBD)

Current treatments for inflammatory bowel disease (IBD) include targeted biologic therapies, optimization of older therapies, and a step-up approach to aggressive therapies when milder therapies fail or patients declare aggressive disease.

Does the 3-aminobenzamide effect on bacterial translocation affect experimental acute necrotizing pancreatitis?

3-aminobenzamide therapy improves histopathologic score and reduces oxidative stress in experimental pancreatitis, potentially reducing bacterial translocation and promoting healing.

Advanced Oxidation Protein Products: A Novel Marker of Oxidative Stress in Ulcerative Colitis

Increased levels of advanced oxidation protein products (AOPP) in ulcerative colitis patients support the presence of oxidative stress and protein oxidation, and may serve as a simple serum marker to assess disease activity, predict severity, and potentially respond to therapy.

Citations

Indoleamine-2,3-dioxygenase-related anti-inflammatory effects of 3-aminobenzamide and infliximab in experimental colitis.

Infliximab reduces bacterial translocation in experimental colitis by altering indoleamine-2,3-dioxygenase expression, offering a potential new treatment approach for inflammatory bowel disease.

Effect of Silymarin on Cathepsin Activity and Oxidative Stress in TNBS-induced Colitis in Rats

Silymarin effectively reduces oxidative stress and cathepsin activity in TNBS-induced colitis in rats, making it a potential treatment agent for inflammatory bowel diseases.

Effect of colchicine on experimental acetic acid induced

Colchicine may help control inflammation in ulcerative colitis treatment, but its protective effect on antioxidant activity and lipid peroxidation end products were not observed in this study.